MedTrace Logo

Development and Validation of a Disability Severity Index for CMT

NCT01455623 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 291

Last updated 2014-03-26

No results posted yet for this study

Summary

It is necessary for outcome measures to accurately reflect the state of health of a person in order for clinical trials to show benefit. The most commonly used outcome measure for Charcot Marie Tooth Disease (CMT) is the CMT Neuropathy Score, which uses cutoffs of points designated as mild (0-10 points), moderate (11-20) or severe (21-36). These terms are arbitrary. This study is looking to base mild, moderate, and severe on what both people affected with CMT and those who provide for people with CMT consider appropriate.

Conditions

  • Charcot Marie Tooth Disease

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Muscular Dystrophy Association

    collaborator OTHER

  • University of Iowa

    lead OTHER

Principal Investigators

  • Sindhu Ramchandren, MD · Wayne State University

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01455623 on ClinicalTrials.gov